Sigilon’s pipeline of products in hemophilia, lysosomal storage diseases, and, in collaboration with Eli Lilly, type 1 diabetes, are rapidly advancing toward the clinic, and the company is carrying out preclinical studies in other chronic disease indications.
Current therapies for blood disorders like hemophilia involve a high burden to patients, requiring injections as often as multiple times each week over a patient’s lifetime. These therapies do not entirely restore natural protein function, leaving patients vulnerable to long-term complications such as joint damage. These therapies also require frequent infusions. Shielded Living Therapeutics may provide both improved efficacy and improved quality of life for patients with blood disorders.
We are working with Eli Lilly as partner to develop Shielded Living Therapeutics for the treatment of insulin-dependent diabetes. In the Lilly-Sigilon collaboration, Sigilon will create proprietary products comprised of induced pluripotent stem cells, a type of stem cell derived from adult cells, engineered into differentiated insulin-producing pancreatic beta cells and encapsulated using Sigilon’s Afibromer technology. The goal of these products will be to restore insulin production over sustained periods.
Under the terms of the agreement, Lilly will receive an exclusive worldwide license to Sigilon’s Afibromer technology for islet cell encapsulation. Sigilon will be responsible for all development activities and costs related to the collaboration until submission of an investigational new drug application (IND). After an IND is submitted, Lilly will be responsible for all clinical development and commercialization activities and costs related to the collaboration.
There are over 50 lysosomal storage disorders. While some diseases such as Fabry disease and Gaucher disease do have treatments available, the vast majority of these diseases do not have commercially available treatments. Our proprietary cell line for lysosomal storage disorders should enable the ability to create treatments for many of these diseases when biologically feasible, potentially providing new therapies for those not yet treated. For those diseases with available treatments, we aim to provide better efficacy and better patient outcomes by providing consistent delivery of therapeutics, avoiding the peaks and troughs associated with present-day treatments.